A study on luseogliflozin for type 2 diabetes
Part of Hormones & metabolism clinical trials.
This trial is looking at how well a diabetes medicine called luseogliflozin works and how tolerable it is for people with type 2 diabetes. It includes patients who have already started taking the drug as part of their regular care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have type 2 diabetes.
- You started taking luseogliflozin between 7 and 30 days before joining the study.
- You have had some blood work and measurements (like HbA1c, kidney function, blood pressure, and weight) done within 15 days of starting the drug.
- You are not pregnant, breastfeeding, or planning pregnancy during the study and for two months after.
- You do not have severe kidney problems (eGFR less than 30) or other serious conditions like ketoacidosis or active cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication called LID104 added to your usual metformin to see if it improves blood sugar control in people with type 2 diabetes. If you qualify, you'll get the study drug or a placebo (inactive pill) to compare how well it works.
This study tests how safe and effective the diabetes medication henagliflozin is for Chinese patients with type 2 diabetes. It is an observational study, meaning you will continue your regular care while researchers watch your progress.
This trial tests how stopping a type 2 diabetes medication called an SGLT2 inhibitor affects the liver's production of sugar and ketones. It may help understand better ways to manage diabetes.
This trial studies whether erugliflozin can reduce liver fat and liver scarring (fibrosis) while also improving blood sugar in people with type 2 diabetes and fatty liver disease (NASH/NAFLD). It’s designed for people who haven’t used certain diabetes medicines like SGLT2 inhibitors or insulin before.
This study tests how a type of diabetes medicine called SGLT2 inhibitors affects how the liver makes sugar. It may help researchers better understand how to manage blood sugar in people with type 2 diabetes.
This trial tests a medication called empagliflozin (a type 2 diabetes pill) to see how well it works in people with type 2 diabetes who have not taken any diabetes drugs for at least 8 weeks. If you qualify, you may receive the study drug and help researchers learn more about managing blood sugar.
Hear when a new Type 2 Diabetes Mellitus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.